Investigational Drug Information for Buparlisib
What is the drug development status for Buparlisib?
Buparlisib is an investigational drug.
There have been 40 clinical trials for Buparlisib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 12th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
Summary for Buparlisib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,341 |
| WIPO Patent Applications | 1,061 |
| Japanese Patent Applications | 176 |
| Clinical Trial Progress | Phase 3 (2020-12-12) |
| Vendors | 72 |
Recent Clinical Trials for Buparlisib
| Title | Sponsor | Phase |
|---|---|---|
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | Adlai Nortye Biopharma Co., Ltd. | Phase 3 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Janssen Scientific Affairs, LLC | Phase 1 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Novartis Pharmaceuticals | Phase 1 |
Clinical Trial Summary for Buparlisib
Top disease conditions for Buparlisib
Top clinical trial sponsors for Buparlisib
US Patents for Buparlisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Buparlisib Development Update, Patent Position, and Market Projection
Buparlisib, also known as BKM120, is an oral pan-class I phosphatidylinositol 3-kinase inhibitor developed by Novartis. Its clinical program has been discontinued after negative or commercially inadequate results in breast cancer and glioblastoma. Buparlisib has no FDA-approved indication, no Orange Book-listed product, no established commercial revenue base, and no identified active late-stage development program through June 2024. Its near-term market projection is effectively zero unless a new sponsor revives the asset for a biomarker-selected or central nervous system indication.
What is the current development status of buparlisib?
Buparlisib is not an approved medicine and is not marketed in the United States, European Union, or other major pharmaceutical markets.
Novartis evaluated buparlisib across multiple solid and hematologic malignancies, with the largest program in hormone receptor-positive, HER2-negative advanced breast cancer. The principal strategy was to combine buparlisib with endocrine therapy after progression on an aromatase inhibitor or other hormonal treatment.
The development program produced limited efficacy gains and substantial toxicity. Novartis did not advance buparlisib to commercialization after the pivotal breast cancer program failed to establish a favorable benefit-risk profile.
| Item | Buparlisib status |
|---|---|
| Active ingredient | Buparlisib, BKM120 |
| Mechanism | Oral pan-class I PI3K inhibitor |
| Originator | Novartis |
| FDA approval | None |
| EMA marketing authorization | None |
| Approved indication | None |
| Orange Book listing | None |
| Commercial sales | None for an approved product |
| Principal clinical focus | HR-positive/HER2-negative advanced breast cancer |
| Development outcome | Commercial development discontinued |
| Biosimilar exposure | None; buparlisib is a small molecule |
| Generic exposure | No marketed generic because no approved reference product exists |
ClinicalTrials.gov records show that buparlisib was studied in breast cancer, glioblastoma, acute leukemia, lymphoma, ovarian cancer, prostate cancer, non-small-cell lung cancer, and other tumors. Most programs were early-stage or were terminated after the failure of the lead oncology strategy.
Why did buparlisib fail in breast cancer?
The key breast cancer trials were BELLE-2 and BELLE-3. Both evaluated buparlisib with fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer previously treated with endocrine therapy.
BELLE-2 trial
BELLE-2 was a Phase III study of buparlisib plus fulvestrant versus placebo plus fulvestrant in patients whose disease had progressed on or after aromatase inhibitor treatment.
The trial demonstrated a statistically significant progression-free survival improvement in the overall population. The magnitude of benefit was modest, while adverse events were frequent. Reported toxicities included hyperglycemia, mood alterations, anxiety, depression, liver enzyme elevations, and other treatment-related events.
An exploratory analysis suggested greater activity in patients with PIK3CA-mutated circulating tumor DNA. That signal was not sufficient to overcome the broader safety and efficacy limitations or create a clear regulatory pathway for an unselected population. [1]
BELLE-3 trial
BELLE-3 evaluated buparlisib plus fulvestrant after progression on an mTOR inhibitor. The combination improved median progression-free survival compared with fulvestrant alone, but the treatment effect was limited and toxicity remained material.
The trial reinforced the central development problem: buparlisib could inhibit the PI3K pathway, but its broad target profile and central nervous system penetration created safety liabilities that reduced its commercial value. [2]
Breast cancer development assessment
| Factor | Effect on buparlisib |
|---|---|
| PFS signal | Positive in selected Phase III settings |
| Overall survival | No compelling improvement supporting broad use |
| CNS penetration | Pharmacologically useful but increased neuropsychiatric concerns |
| Hyperglycemia | Clinically significant class-related toxicity |
| Psychiatric adverse events | Important barrier to chronic use |
| Biomarker strategy | PIK3CA mutation signal, but not sufficient for approval |
| Competitive position | Weaker than more selective PI3K-alpha inhibitors |
| Regulatory outlook | Insufficient for approval |
The commercial opportunity moved toward more selective PI3K inhibitors. Alpelisib, a PI3K-alpha inhibitor, received FDA approval in 2019 for PIK3CA-mutated, HR-positive/HER2-negative advanced or metastatic breast cancer in combination with fulvestrant. That approval established a more focused therapeutic and biomarker strategy than buparlisib's pan-PI3K approach. [3]
What happened in glioblastoma and other tumors?
Buparlisib was also tested in glioblastoma because the drug crosses the blood-brain barrier. That characteristic distinguished it from many systemic PI3K inhibitors but did not translate into a successful commercial indication.
The drug was evaluated in recurrent glioblastoma and in combination strategies involving chemotherapy or radiotherapy. Studies generally failed to show a clinically meaningful improvement sufficient for late-stage development. Central nervous system toxicity, limited single-agent activity, tumor heterogeneity, and pathway redundancy reduced the probability of success.
Other exploratory programs included:
- Acute myeloid leukemia and other hematologic malignancies
- Non-small-cell lung cancer
- Ovarian cancer
- Prostate cancer
- Head and neck cancer
- Endometrial and other solid tumors
No program produced an approved indication. The broad clinical record suggests that buparlisib's development was limited by target validation, tolerability, and competition rather than by a lack of biological activity alone.
When did buparlisib lose commercial exclusivity?
Buparlisib did not lose market exclusivity through generic competition because it never reached approval.
A patent expiry date cannot be treated as a commercial exclusivity date for this asset. Patent families covering buparlisib may include composition-of-matter, pharmaceutical composition, therapeutic-use, and manufacturing claims, but the absence of an approved product means there is no FDA regulatory exclusivity period to calculate.
The relevant distinction is:
| Exclusivity category | Buparlisib position |
|---|---|
| New chemical entity exclusivity | Never granted |
| New clinical investigation exclusivity | Never attached to an approved product |
| Orphan-drug exclusivity | No approved orphan indication identified |
| Patent term extension | No approved product eligible for extension |
| Orange Book patent listing | None |
| Pediatric exclusivity | None |
| Generic Paragraph IV pathway | Not commercially relevant without an approved reference listed drug |
Any remaining patent rights would be relevant to a future licensing or revival transaction, but they would not create an active pharmaceutical market on their own. Patent enforceability would depend on claim scope, prosecution history, terminal disclaimers, maintenance fees, national-phase status, and remaining term in each jurisdiction.
What patents protect buparlisib?
Buparlisib was developed by Novartis, and patent protection would be expected to cover the active chemical entity and related pharmaceutical uses. Public clinical and corporate records identify Novartis as the principal originator, but the available development record does not establish a complete, current patent-family schedule with verified U.S. patent numbers and expiration dates.
The likely patent categories are:
Composition-of-matter patents
These would cover buparlisib itself, defined chemical salts, stereoisomers, solvates, or related compounds. Composition claims generally provide the strongest protection because they can prevent use of the active ingredient across indications.
Pharmaceutical composition patents
These may cover oral dosage forms, excipients, solid-state forms, particle characteristics, or dosage regimens. Their practical value would depend on whether a future product uses the claimed formulation.
Method-of-use patents
Potential use claims could cover treatment of cancer, PI3K-dependent tumors, PIK3CA-mutated disease, glioblastoma, or combinations with fulvestrant, chemotherapy, radiotherapy, or other targeted therapies.
Manufacturing patents
Process claims may cover intermediates, synthetic routes, purification, crystallization, or scale-up methods. These claims could increase supply-chain friction but would rarely prevent a generic manufacturer from developing a non-infringing route if composition claims have expired.
Because buparlisib has no approved reference product, there is no Orange Book patent-certification framework comparable to that for marketed small-molecule drugs. A future sponsor would need to conduct a jurisdiction-specific patent clearance review before restarting development or seeking approval.
What is the FDA regulatory status of buparlisib?
The FDA has not approved buparlisib for any disease. No New Drug Application has resulted in a commercial approval, and no FDA-approved labeling exists.
The regulatory barriers are substantial:
- A sponsor would need to select a commercially credible indication.
- The program would require new clinical evidence, not simply reliance on historical exploratory studies.
- A biomarker-defined population would likely be necessary to improve the benefit-risk profile.
- Neuropsychiatric and metabolic risks would require intensive monitoring.
- The sponsor would face competition from approved or advancing selective PI3K-pathway inhibitors.
The historical trial data may support scientific rationale or retrospective biomarker analysis, but they do not provide a straightforward approval route.
Are there Paragraph IV challenges or generic launch risks?
There is no meaningful Paragraph IV litigation profile for buparlisib because no buparlisib reference product is listed in the FDA Orange Book.
Generic launch risk is therefore different from the risk associated with an approved branded drug:
- There is no current branded revenue to erode.
- There is no approved dosage form for an ANDA applicant to copy.
- There is no established FDA reference listed drug.
- A future sponsor would need to create a new regulatory and commercial market.
- Patent risk would depend on surviving composition and use claims rather than on Orange Book-listed patents.
If buparlisib were revived and approved, generic competition would likely depend on the remaining term of any valid composition-of-matter patent. Formulation and method-of-use claims could delay or complicate entry but would be less durable than a valid compound patent.
How does buparlisib compare with competing PI3K inhibitors?
Buparlisib's competitive weakness is its lack of selectivity and its tolerability profile.
| Drug | Primary target | Regulatory position through June 2024 | Commercial assessment |
|---|---|---|---|
| Buparlisib | Pan-class I PI3K | Not approved | Development discontinued |
| Alpelisib | PI3K-alpha | FDA approved for PIK3CA-mutated HR-positive/HER2-negative breast cancer | Established targeted-market position |
| Duvelisib | PI3K-delta/gamma | Approved in certain hematologic malignancies; U.S. commercial status weakened after withdrawal actions | Narrower hematology opportunity |
| Idelalisib | PI3K-delta | Approved in hematologic malignancies | Safety restrictions and declining use |
| Umbralisib | PI3K-delta/CK1-epsilon | U.S. approval withdrawn | Commercially unsuccessful |
| Inavolisib | PI3K-alpha pathway strategy | Not included in the June 2024 cutoff | Potentially stronger biomarker-focused competition |
Buparlisib's pan-PI3K activity provided broad pathway coverage, but that breadth also contributed to toxicity. Selective inhibitors have a clearer patient-selection framework and a more defensible regulatory strategy.
What is the market projection for buparlisib?
The base-case market projection is zero through the medium term because no sponsor has an active commercial development program and the drug has no approved indication.
Base case: no revival
Under the most likely scenario, buparlisib remains an abandoned investigational compound. Revenue remains zero, and the asset has value mainly as:
- A licensing candidate for a CNS oncology platform
- A research tool for PI3K pathway biology
- A combination partner in biomarker-driven trials
- A potential source of chemical or intellectual property rights
Upside case: biomarker-selected revival
A revival would require a new sponsor to demonstrate that buparlisib's CNS penetration or pan-PI3K activity creates a benefit not available from selective inhibitors. Plausible areas could include:
- PI3K-pathway altered glioblastoma
- Brain metastases from breast cancer
- PIK3CA-mutated tumors with CNS involvement
- Combination treatment with immunotherapy or radiation
- Molecularly selected hematologic malignancies
This scenario has low probability because it would require fresh clinical investment, a narrower safety-managed population, and differentiation from approved competitors.
Commercial valuation implications
| Scenario | Probability assessment | Revenue outlook |
|---|---|---|
| Continued abandonment | Highest | Zero |
| Academic or investigator-led research | Moderate | Minimal or none |
| Regional licensing for niche development | Low | Pre-commercial milestone value only |
| Full clinical revival | Very low | Potential revenue several years after successful trials |
| Broad oncology approval | Remote | Not a credible base case |
A theoretical peak-sales estimate would be misleading without an active sponsor, defined indication, regulatory pathway, and validated biomarker. The actionable commercial conclusion is that buparlisib has no current pharmaceutical revenue exposure.
What licensing deals involve buparlisib?
Novartis is the principal company associated with buparlisib development. No major disclosed out-licensing transaction has established an active commercial successor for the asset through June 2024.
The absence of a disclosed licensing deal matters because a restart would likely require:
- Rights transfer or regional licensing from the original owner
- Access to clinical data and regulatory correspondence
- Confirmation of patent ownership and surviving claims
- New toxicology and manufacturing planning
- A revised clinical development strategy
Without a rights transaction or a new sponsor announcement, buparlisib should be treated as a discontinued Novartis asset rather than an emerging competitor.
What is the litigation status of buparlisib?
No active, commercially significant Paragraph IV litigation or product-launch dispute is associated with buparlisib through June 2024. The lack of an approved product has prevented the patent-litigation cycle normally seen before generic entry.
Potential future disputes would most likely concern:
- Ownership of compound or use patents
- License rights
- Patent term and national-phase status
- Use of historical clinical data
- Infringement by a revived product or competing PI3K program
There is no current litigation event that changes the asset's market outlook.
Key Takeaways
- Buparlisib is an unapproved Novartis pan-PI3K inhibitor.
- The principal Phase III breast cancer trials produced modest PFS benefits with significant toxicity.
- Development was discontinued after the program failed to support a commercially viable regulatory strategy.
- Buparlisib has no FDA approval, Orange Book listing, regulatory exclusivity, or commercial sales.
- No meaningful Paragraph IV or generic-entry risk exists today.
- Patent rights may remain in selected jurisdictions, but they do not create an active market.
- A new development program would need a biomarker-defined indication, likely involving CNS disease or a highly selected PI3K-altered population.
- The base-case market projection is zero revenue through the medium term.
- Buparlisib's principal residual value is as a licensing or research asset, not as a near-term commercial drug.
FAQs About Buparlisib Development and Market Potential
Is buparlisib still being developed?
No active late-stage commercial development program has been identified through June 2024. The original Novartis oncology program was discontinued.
Can buparlisib be prescribed for cancer?
No. Buparlisib has no FDA-approved indication and is not an approved commercial cancer medicine.
Does buparlisib have a generic version?
No marketed generic version exists. Buparlisib has no approved reference product in the United States.
Is buparlisib more effective than alpelisib?
No direct head-to-head comparison establishes superiority. Alpelisib has a narrower PI3K-alpha mechanism, an FDA-approved biomarker-defined indication, and a stronger current commercial position.
Could buparlisib return to clinical development?
A return is possible only through a new sponsor, rights transaction, and redesigned biomarker-driven program. The commercial probability is low because of historical toxicity, limited efficacy, and competition from selective PI3K inhibitors.
References
-
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., DeLaurentiis, M., Jiang, Z., et al. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer previously treated with aromatase inhibitors: Phase 3, randomized, double-blind, placebo-controlled BELLE-2 trial. The Lancet Oncology, 18(7), 904-916.
-
Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lønning, P. E., Boccardo, F., et al. (2018). Buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition: Phase 3 BELLE-3 trial. The Lancet Oncology, 19(1), 87-100.
-
U.S. Food and Drug Administration. (2019). FDA approves alpelisib for metastatic breast cancer. FDA.
-
ClinicalTrials.gov. (n.d.). Studies involving buparlisib (BKM120). U.S. National Library of Medicine.
-
Novartis AG. (2016). Annual report 2016. Basel, Switzerland: Novartis.
More… ↓
